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Abstract In non-ST-elevation acute coronary syndromes
(ACS), an early invasive strategy is recommended for
middle/high-risk patients; however, the optimal timing for
coronary angiography is still debated. The aim of this study
was to evaluate the prognostic implications of the time of
angiography in ACS patients treated in accord with an
early invasive strategy. We analyzed the relationship
between the time of angiography and outcomes at follow-
up in 517 ACS patients, of whom 482 were revascularized
with percutaneous coronary intervention (PCI) (86.9%) or
coronary artery by-pass graft (13.1%). We also evaluated
the influence of clinical, biohumoral and angiographic
variables on the patients’ outcomes at follow-up. Among
patients submitted to angiography at different time inter-
vals from both hospital admission and symptom onset,
significant differences neither in mortality nor in cardiac
ischemic events at follow-up were observed. At univariate
analysis, complete versus partial revascularization, longer
hospital stay, higher TIMI risk score, diabetes mellitus,
higher discharge creatinine and admission anemia were
associated with mortality and cardiac ischemic events at
follow-up; a lower left ventricular ejection fraction was
associated with mortality; higher peak troponin I and pre-
vious PCI were associated with cardiac ischemic events at
follow-up. At multivariate analysis longer hospital stay,
higher discharge creatinine levels, and previous PCI were
independent predictors of cardiac ischemic events at fol-
low-up. Our evaluation in ACS patients treated with an
early invasive strategy does not support the concept that
angiography should be performed as soon as possible after
symptom onset or hospital admission. Rather, an unfavor-
able long-term outcome is influenced principally by the
clinical complexity of patients.
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Introduction
Current international guidelines on the management of
non-ST elevation acute coronary syndromes (ACS) rec-
ommend, especially for high-risk patients, an early inva-
sive strategy [1, 2], according to which patients quickly
undergo coronary angiography, and, if necessary, early
percutaneous coronary intervention (PCI) or surgical
revascularization (CABG).
An early invasive strategy has been shown to improve
long-term survival and reduce the risk of late myocardial
infarction and rehospitalization [3–8] in comparison with a
selectively invasive approach, according to which coronary
angiography is performed only for recurrent ischemia or
new-onset left ventricular dysfunction.
However, the optimal timing for coronary angiography
in such patients is still unknown [8, 9], and in daily prac-
tice, there is a wide variation in interpreting the term
‘‘early’’. In some hospitals, ACS patients are rapidly
transferred from the Emergency Department (ED) to the
catheterization laboratory, whereas in others they may wait
for coronary angiography up to a week, as suggested by
FRISC II investigators [3].
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According to recommendations of the American and
European Guidelines, in the past few years, an early
invasive strategy has been adopted systematically in all
patients admitted to our Institution for non-ST-elevation
myocardial infarction (NSTEMI) or unstable angina (UA)
judged at high or middle risk according to a TIMI risk
score C 3 [10].
The aim of the present study was to evaluate the prognostic
implications of the time of angiography in patients with ACS,
treated in accord with an early invasive strategy, during a
median 13-month follow-up. Moreover, we analyzed the
influence of some clinical, biohumoral, angiographic and
procedural variables on patient’s long-term outcome.
Methods
From January 2005 to December 2006, 554 ACS patients
were consecutively admitted to the Cardiac Step Down
Unit (CSDU) of the University of Florence: 346 (62.4%)
were directly addressed to our CSDU from the ED, while
208 (37.5%) were referred to our Institution from other
hospitals.
Patients were enrolled in the study if they had ischemic
symptoms lasting C10 min within 24–48 h before admis-
sion to the CSDU, or cardiac troponin I (TnI) or CK-MB
level elevation above the upper limits of normal, or tran-
sient ST segment shift on an electrocardiogram.
Patients with an urgent indication for coronary angiog-
raphy, such as those with signs and symptoms of acute
heart failure, hemodynamic instability, persistence of
ischemic symptoms despite medical therapy or life-
threatening arrhythmias, were excluded from the study.
Out of 554 patients, 517 (93.3%) underwent coronary
angiography. In 37 patients, this invasive procedure was
not performed because of major contraindications, serious
comorbidities, or very recent surgery. In 482 ACS patients
submitted to angiography, revascularization was performed
with either PCI (86.9%) or CABG (13.1%). In the
remaining 35 patients, revascularization was not performed
because it was unnecessary, it was refused by the patients,
or it was contraindicated because of comorbidities. All
patients were discharged with optimal medical therapy,
including antithrombotic agents, statins, beta-blockers, and
angiotensin-converting enzyme inhibitors, unless individ-
ually contraindicated.
Coronary angiography and angioplasty were performed
using standard techniques, usually by the femoral or radial
approach. All patients received a 325-mg of acetyl-sali-
cylic acid and 300 mg of clopidogrel loading dose at
admission in CSDU or in the catheterization laboratory.
Glycoprotein IIb–IIIa inhibitors were used at the operator’s
discretion in 72 patients (17.2%).
For each patient, the timing of angiography, clinical,
biohumoral (creatinine and hemoglobin on admission and
at discharge, glycemia and TnI on admission and at the
peak), angiographic, and procedural data were collected.
Two different times of angiography were considered: with
respect to angiography, ‘‘timing of angiography’’ was
defined as the time interval from admission to CSDU while
‘‘delay of angiography’’ was the time interval from
symptoms onset. Data regarding the delay of angiography
were available in 487/517 patients. Two physicians col-
lected by phone the follow-up data in 509 out of 554
patients (93%) after a median follow-up period of
13 months (25th–75th percentile: 8–21 months). Apart
from mortality, the cardiovascular events reported by the
patients themselves, or by their relatives were then verified,
in a blinded manner, by means of hospital records.
The study protocol was approved by the hospital ethics
committee, and informed consent was obtained from each
patient before enrolling in the study. Investigations were
conducted in accordance with the Declaration of Helsinki.
UA and NSTEMI were diagnosed according to recent
Guidelines [1, 11] (the normal value of TnI in our labo-
ratory is \0.15 ng/ml).
Statistical analysis was performed using SPSS for
Windows, version 11.5 (SPSS, Inc., Chicago, IL, USA). A
P value \ 0.05 was considered statistically significant.
Data were expressed as frequencies and percentages, or
median (25th–75th percentile). To evaluate differences in
clinical, biohumoral and angiographic data, patients were
divided into three groups of timing (\6, 6–24and [24 h)
and delay (\24, 24–48 and [48 h) of angiography and v2
or Kruskal–Wallis tests were used for univariate analysis;
post-tests (Z-score for discrete variables and Kruskal–
Wallis, comparing one group with one another in turn, for
continuous data) were performed when overall significance
was less than 10%. Age (categorically divided into B75 and
[75 years) and gender-adjusted Kaplan–Meier survival
analyses were performed, as previously reported [12], to
evaluate differences in mortality during follow-up in rela-
tion to both timing and delay of angiography within or
beyond 24 h; these differences were assessed by means of a
log-rank test. After assessment of risk proportionality,
several univariate Cox regression analyses were performed
to investigate relationships between clinical, biohumoral
and procedural variables, and outcomes. To evaluate
potential adjusted predictors of non-fatal cardiac ischemic
events at follow-up, (angina or acute myocardial infarc-
tion), baseline variables, considered clinically relevant and
showing a statistically significant association with outcome
at univariate analysis, were entered into a multivariate Cox
proportional regression analysis. Candidate variables were
carefully chosen, considering the number of events, to
ensure parsimony of the final model; both the timing and,
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respectively, the delay of angiography were forced into the
final models. Non-significant variables were dropped by
means of backward selection.
Results
The study population consisted of 554 ACS patients, out of
whom 391 were men, (70.8%), median age 73 years (25th-
75th percentile 64–78).UA was diagnosed in 415 cases
(74.9%) at admission, and in 250 cases (45.1%) at dis-
charge. About 70% of the patients were hypertensive, and
43% of them were dyslipidemic.
The cardiovascular risk of our patients was estimated
according to TIMI risk score: most of them (72.2%) were at
intermediate risk (TIMI risk score 3–4), and 22.2% at high
risk (TIMI risk score 5–7).
The distribution of ACS patients according to the timing
and the delay of angiography was different in fact, con-
sidering the timing of angiography, 397 patients (76.8%)
were submitted to angiography earlier than 24 h, and 120
(23.2%) later than 24 h from admission to the CSDU, while
considering the delay of angiography, more than 60% of
patients were submitted to angiography later than 24 h from
symptom onset. Among the possible causes why patients
were submitted to angiography later than 24 h from CSDU
admission, the following were observed: arrival at our
hospital during the night hours or during holidays (n = 64),
presence of severe comorbidities (n = 26), pending arrival
of relatives before giving consent (n = 30).
In Tables 1 and 2, data of ACS patients submitted to
coronary angiography are reported in relation to the dif-
ferent timing of angiography (\6, 6–24 and [24 h) and
delays of angiography (\24, 24–48 and [48 h). No sig-
nificant difference in baseline characteristics was found in
relation to the different timing and delays of angiography,
except for a significantly lower percentage of patients with
concomitant neoplasia and higher values of TnI at admis-
sion in the subgroup of those submitted to angiography
earlier than 6 h from admission in the CSDU (Table 1),
and for significantly higher values of TnI both at admission
and at the peak in patients treated with a shorter delay from
symptom onset (Table 2).
Tables 3 and 4 show angiographic and procedural data
of patients submitted to coronary angiography, and treated
with PCI according to the timing and delay of angiography.
No significant difference in angiographic and procedural
variables was found in relation to the different timing and
delays of angiography, except for a significantly higher
percentage of patients in whom a complete revasculariza-
tion was performed with a delay of angiography \24 h;
moreover, in this group of patients, the culprit lesion was
less frequently determined by a restenosis with respect to
patients submitted to angiography later than 24 h from
symptom onset (Table 4).
Moreover, no significant difference was observed in the
pharmacological treatment in relation to the different tim-
ing and delays of angiography (data not shown).
The median follow-up length was 13.1 months (25th–
75th percentile 8.4–21.0 months).
The in-hospital mortality as well as the mortality and the
cardiac ischemic events at follow-up are summarized in
Fig. 1.
No significant difference was observed in mortality
during follow-up (Log Rank chi square 0.682; P = 0.409;
Kaplan–Meier analysis adjusted for age and gender)
(Fig. 2, Panel A) as well as in the incidence of angina and
non-fatal myocardial infarction at follow-up (23.0 vs.
26.3%; P = 0.545) between patients submitted to angiog-
raphy \ or[24 h from admission in the CSDU (timing of
angiography). Even when an earlier treatment (\6 h) was
compared with a delayed one ([24 h), at logistic regression
analysis, the timing of angiography was not a predictor of
mortality (OR 1.69; 95% CI 0.54–5.23; P = 0.365). Sim-
ilarly, at univariate analysis, the timing of angiography did
not predict ischemic relapse at follow-up (OR 1.06; 95% CI
0.65–1.73; P = 0.824).
Similarly, no significant difference in ACS patients
mortality was seen in relation to a delay of angiogra-
phy \ or [ 24 h either in the acute phase (2.1 vs. 1.4%,
respectively) or during follow-up (Log Rank chi square
0.584; P = 0.445; Kaplan–Meier analysis adjusted for age
and gender) (Fig. 2, Panel B). Moreover, no significant
difference was observed in the incidence of angina and
myocardial infarction at follow-up among the two groups
of patients (25.7 and 29.8% for patients treated with a delay
of angiography \ or [ than 24 h, respectively).
Recurrence of cardiac ischemic events (angina or non-
fatal myocardial infarction) at follow-up were significantly
more frequent in patients with a previous PCI.
As far as the relationship between overall mortality and
TnI is concerned, a positive trend between higher TnI levels
at admission and an increased mortality was observed;
moreover, increased mortality was also observed between
patients with TnI at the peak [5.00 ng/mL versus those
with normal values (P \ 0.05).
Moreover, considering the relationship between other
biohumoral data and mortality, serum creatinine and glu-
cose values at admission were significantly higher in
patients who died than in survivors [1.4 (95% CI 1.1–1.8)
vs. 1.0 (95% CI 0.9–1.2) mg/dl; P \ 0.001 and 1.21
(95% CI 1.00–1.62) vs. 1.04 (95% CI 0.91–1.27) g/dl;
P = 0.001, respectively)]. Creatinine levels at discharge
were significantly higher in dead patients than in survivors
[1.3 mg/dl (95% CI 1.0–2.1) vs. 1.0 mg/dl (95% CI
0.9–1.2); (P \ 0.001)]. Hemoglobin values were significantly
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lower in patients who die than in survivors both on
admission and at discharge (11.8 vs. 13.1 g/dl; P = 0.023
and 11.0 vs. 12.2 g/dl; P = 0.013, respectively).
At univariate analysis, the following variables were
unadjusted predictors of mortality and cardiac ischemic
events at follow-up: length of CSDU stay (1 day increase),
TIMI Risk Score (1 unit increase), diabetes mellitus, dis-
charge creatinine (1 mg/dl increase), admission anemia,
complete versus partial revascularization (Fig. 3). More-
over, a lower admission left ventricular ejection fraction
(LVEF) was associated with mortality at follow-up, and a
previous PCI and increased peak TnI were associated with
cardiac ischemic events at follow-up. Both the timing of
angiography ([24 vs.\24 h), and the delay of angiography
([24 vs. \24 h) were not significantly associated with
either mortality or cardiac ischemic events at follow-up
(Fig. 3).
At multivariate analysis, 12 variables, whose association
with cardiac ischemic events at follow-up was clinically
relevant or statistically significant, were found on two
backward stepwise Cox regression analyses: in this model,
the timing and delay of angiography were forced as
covariates. The length of CSDU stay (1 day increase; HR
1.19, 95% CI 1.10–1.29, P \ 0.001), the creatinine level at
discharge (1 mg/dl increase; HR 1.61, 95% CI 1.02–2.55,
P = 0.043), and a previous PCI (HR 1.91, 95% CI
1.32–2.75, P \ 0.001) were independent predictors of
cardiac ischemic events at follow-up when adjusted for the
timing of angiography ([24 vs. \24 h; HR 0.74, 95% CI
0.41–1.22, P = 0.259). Similarly, length of CSDU stay
(1 day increase; HR 1.19, 95% CI 1.10–1.29, P \ 0.001),
creatinine level at discharge (1 mg/dl increase; HR 1.77,
95% CI 1.07–2.92, P = 0.026), and a previous PCI (HR
1.95, 95% CI 1.34–2.82, P \ 0.001) were also independent
Table 1 Clinical and biohumoral characteristics of patients investigated in relation to timing of angiography
\6 h (n = 352; 68.1%) 6–24 h (n = 45; 8.7%) [24 h (n = 120; 23.2%) P value (v2 or KW)
Age [years; median (IR)] 73 (63–78) 72 (64–78) 72 (63–78) 0.935
Males [% (95% CI)] 70.7 (66.0–75.5) 68.9 (55.4–82.4) 73.3 (65.4–81.2) 0.811
Body weight [kg; median (IR)] 74 (65–80) 75 (68–80) 75 (68–81) 0.971
Hypertension [% (95% CI)] 69.6 (64.8–74.4) 73.3 (60.4–86.3) 73.3 (65.4–81.2) 0.685
Diabetes mellitus [% (95% CI)] 28.7 (24.0–33.4) 15.6 (5.0–26.1) 29.2 (21.0–37.3) 0.164
Dyslipidemia [% (95% CI)] 41.2 (36.1–46.3) 44.4 (29.9–59.0) 48.3 (39.4–57.3) 0.388
Family history of CAD [% (95% CI)] 24.4 (19.9–28.9) 28.9 (15.6–42.1) 28.3 (20.3–36.4) 0.615
Smoking habit [% (95% CI)] 34.6 (29.7–39.6) 40.0 (25.7–54.3) 36.7 (28.0–45.3) 0.750
Chronic renal failure [% (95% CI)] 6.3 (3.7–8.8) 8.9 (0.6–17.2) 10.0 (4.6–15.4) 0.364
Neoplasia [% (95% CI)] 4.3 (2.2–6.4) 15.6 (5.0–26.1)* 5.8 (1.6–10.0) 0.008
Previous AMI [% (95% CI)] 33.5 (28.6–38.5) 40.0 (25.7–54.3) 30.0 (21.8–38.2) 0.471
Previous PCI [% (95% CI)] 31.3 (26.4–36.1) 37.8 (23.6–51.9) 43.3 (34.5–52.2) 0.052
TIMI Risk Score 1–2 [% (95% CI)] 4.0 (1.9–6.0) 6.7 (-0.6–14.0) 9.2 (4.0–14.3) 0.088
TIMI Risk Score 3–7 [% (95% CI)] 96.0 (94.0–98.1) 93.3 (86.0–100.6) 90.8 (85.7–96.0)
Multivessel disease [% (95% CI)] 78.1 (73.8–82.4) 77.8 (65.6–89.9) 72.5 (64.5–80.5) 0.446
Admission LVEF [%;median (IR)] 55 (47–60) 53 (45–60) 55 (45–60) 0.891
Discharge LVEF [%;median (IR)] 55 (48–60) 53 (45–60) 55 (45–60) 0.761
Admission TnI [ng/ml; median (IR)] 0.12 (0.02 -1.33) 0.14 (0.02–3.04) 0.04 (0.01–0.27) 0.012
Peak TnI [ng/ml; median (IR)] 0.91 (0.17–6.32) 0.79 (0.14–5.18) 0.44 (0.10–1.92) 0.055
Admission creatinine [g/dl; median (IR)] 1.00 (0.90–1.20) 1.10 (0.90–1.25) 1.10 (0.90–1.30) 0.113
Discharge creatinine [g/dl; median (IR)] 1.00 (0.90–1.20) 1.00 (0.90–1.15) 1.00 (0.90–1.00) 0.796
Admission Hb [g/dl; median (IR)] 13.4 (11.9–14.4)§ 12.7 (11.0–13.7)§ 13.2 (12.0–14.2) 0.092
Discharge Hb [g/dl; median (IR)] 12.3 (11.0–13.4) 12.2 (10.7–13.1) 12.1 (11.0–13.1) 0.402
Admission glycemia [mg/dl; median (IR)] 104 (90–123) 110 (92–139) 106 (92–133) 0.273
Peak glycemia [mg/dl; median (IR)] 129 (110–166) 128 (108–160) 133 (109–165) 0.697
Discharge glycemia [mg/dl; median (IR)] 102 (92–130) 102 (91–124) 103 (91–124) 0.610
KW Kruskal–Wallis, IR interquartile range, AMI acute myocardial infarction, PCI percutaneous coronary intervention, LVEF left ventricle
ejection fraction, Tn troponin, Hb hemoglobin
* Z-score 2.82, P \ 0.01 versus timing \6 and [24 h
§ P \ 0.05 timing \6 versus 6–24 h
 P \ 0.05 timing \6 versus [24 h
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predictors of cardiac ischemic events at follow-up when
adjusted for a delay of angiography ([24 vs. \24 h; HR
1.11, 95% CI 0.74–1.66, P = 0.630).
Discussion
The main finding of the present study is that, considering
the time to angiography from CSDU admission or the delay
from the onset of symptoms, early coronary angiography
does not affect either short-term or long-term outcome in
these patients. Moreover, several clinical and biohumoral
variables, indicative of each patient’s risk, as well as the
type of revascularization, are associated with both mor-
tality and cardiac ischemic events during follow-up.
Our analysis in ACS patients does not support the need
to perform coronary angiography as soon as possible after
symptom onset or hospital admission, different from those
patients presenting with an ST elevation myocardial
infarction. Such finding can be explained, at least in part,
by the pathogenesis of non-ST elevation ACS [1, 13–15]
being generally due to a partially occlusive thrombus
causing distal microembolization or, less frequently, to an
occlusive thrombus in the presence of an extensive col-
lateral blood supply. Both conditions allow the mainte-
nance of some degree of myocardial perfusion, thus
preventing extensive necrosis. The angiographic findings in
our patients confirmed this explanation; in fact, only 8.4%
of our patients showed a TIMI flow 0 in the culprit vessel.
Our results are in agreement with the primary end-point
of the recently published TIMACS study [16], even though
we used a different scoring system for patients’ risk strati-
fication, and different time intervals were used to consider
an invasive strategy ‘‘delayed’’. The TIMACS study shows,
Table 2 Clinical and biohumoral characteristics of patients investigated in relation to delay of angiography
\24 h (n = 167; 34.3%) 24–48 h (n = 66; 13.6%) [48 h (n = 254; 52.2%) P value (v2 or KW)
Age [years; median (IR)] 70 (60–78) 72 (62–78) 73 (65–78) 0.242
Males [% (95% CI)] 72.5 (65.7–79.2) 66.7 (55.3–78.0) 72.4 (66.9–77.9) 0.625
Body weight [kg; median (IR)] 75 (67–82) 75 (65–80) 73 (67–81) 0.584
Hypertension [% (95% CI)] 71.9 (65.0–78.0) 69.7 (58.6–80.8) 70.1 (64.4–75.7) 0.911
Diabetes mellitus [% (95% CI)] 26.9 (20.2–36.7) 25.8 (15.2–36.6) 28.3 (22.8–33.9) 0.897
Dyslipidemia [% (95% CI)] 39.5 (32.1–46.9) 45.5 (33.4–57.5) 44.1 (38.0–50.2) 0.578
Family history of CAD [% (95% CI)] 28.1 (21.3–35.0) 24.2 (13.9–34.6) 24.4 (19.1–29.7) 0.664
Smoking habit [% (95% CI)] 35.3 (28.1–42.6) 30.3 (19.2–41.4) 37.8 (31.8–43.8) 0.517
Chronic renal failure [% (95% CI)] 7.8 (3.7–11.8) 3.0 (-1.1–7.2) 7.9 (4.6–11.2) 0.372
Neoplasia [% (95% CI)] 7.2 (3.3–11.1) 4.5 (-0.5–9.6) 3.1 (1.0–5.3) 0.161
Previous AMI [% (95% CI)] 29.9 (23.0–36.9) 30.3 (19.2–41.4) 35.4 (29.6–41.3) 0.449
Previous PCI [% (95% CI)] 31.7 (24.7–38.8) 47.0 (34.9–59.0) 33.9 (28.0–39.7) 0.079
TIMI Risk Score 1–2 [% (95% CI)] 3.6 (0.8–6.4) 4.5 (-0.5–9.6) 7.1 (3.9–10.2) 0.287
TIMI Risk Score 3–7 [% (95% CI)] 96.4 (93.6–99.2) 95.5 (90.4–100.5) 92.9 (89.8–96.1)
Multivessel disease [% (95% CI)] 73.1 (66.3–79.8) 74.2 (63.7–84.8) 80.3 (75.4–85.2) 0.189
Admission LVEF [%;median (IR)] 55 (46–60) 55 (42–60) 55 (47–60) 0.716
Discharge LVEF [%;median (IR)] 55 (48–60) 55 (44–60) 55 (50–60) 0.797
Admission TnI [ng/ml; median (IR)] 0.37 (0.03–3.76)§ 0.22 (0.03–1.83) 0.05 (0.01–0.26)§,  \0.001
Peak TnI [ng/ml; median (IR)] 1.30 (0.20–9.31)§ 1.25 (0.26–5.66) 0.44 (0.12–2.26)§,  \0.001
Admission creatinine [g/dl; median (IR)] 1.00 (0.90–1.20) 1.00 (0.90–1.20) 1.00 (0.90–1.30) 0.898
Discharge creatinine [g/dl; median (IR)] 1.00 (0.90–1.20) 1.00 (0.90–1.15) 1.00 (0.90–1.20) 0.990
Admission Hb [g/dl; median (IR)] 13.4 (12.0–14.4)§ 13.0 (11.9–14.4)§ 13.3 (11.8–14.3) 0.786
Discharge Hb [g/dl; median (IR)] 12.3 (11.2–13.2) 11.8 (11.2–13.3) 12.3 (11.0–13.4) 0.705
Admission glycemia [mg/dl; median (IR)] 108 (93–126) 103 (89–126) 103 (90–126) 0.309
Peak glycemia [mg/dl; median (IR)] 130 (111–162) 128 (108–174) 132 (110–166) 0.984
Discharge glycemia [mg/dl; median (IR)] 104 (93–127) 100 (93–133) 102 (91–125) 0.875
KW Kruskal–Wallis, IR interquartile range, AMI acute myocardial infarction, PCI percutaneous coronary intervention, LVEF left ventricle
ejection fraction, Tn troponin, Hb hemoglobin
§ P \ 0.05 delay \24 versus [48 h
 P \ 0.05 delay 24–48 versus [48 h
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in patients treated with an early invasive strategy, a lower
rate of refractory ischemia, an end-point not considered in
our study.
Moreover, the results of our study also are in accord
with those of a recent metanalysis in which no significant
difference in mortality and occurrence of myocardial
infarction was observed between ACS patients treated with
a delayed versus an early invasive approach [17].
However, our findings do not agree with those reported
by Tricoci et al. who found, in a larger number of patients,
a decreased risk in the combined end-point mortality or
myocardial infarction at 1-month follow-up in patients
treated with an early invasive strategy [9]. Our results are
also different from those reported by the ISAR-COOL
investigators who found that a ‘‘very early’’ invasive
strategy was associated with a significantly better outcome
Table 3 Angiographic and procedural characteristics in relation to timing of angiography
\6 h (n = 288; 68.7%) 6–24 h (n = 32; 7.6%) [24 h (n = 99; 23.6%) P value
Coronary artery disease 0.387
One vessel 20.2 (15.5–24.8) 25.0 (10.0–40.0) 28.3 (19.4–37.2)
Two vessels 31.9 (26.6–37.3) 28.1 (12.5–43.7) 20.2 (12.3–28.1)
Three vessels 38.9 (33.3–44.5) 40.6 (23.6–57.6) 41.4 (31.7–51.1)
Left main 9.0 (5.7–12.3) 6.3 (-2.1–14.6) 10.1 (4.2–16.0)
Pre-procedural TIMI flow 0.451
III 1.4 (0.0–2.7%) 3.1 (-2.9–9.2) 2.0 (-0.8–4.8)
II 37.5 (31.9–43.1) 31.2 (15.2–47.3) 38.4 (28.8–48.0)
I 54.5 (48.8–60.3) 56.3 (39.1–73.4) 46.5 (36.6–56.3)
0 6.6 (3.7–9.5) 9.4 (-0.7–19.5) 13.1 (6.5–19.8)
Coronary angioplasty 0.865
1 vessel 60.8 (55.1–66.4) 65.6 (49.2–82.1) 57.6 (47.8–67.3)
2 vessels 24.7 (19.7–29.6) 28.1 (12.5–43.7) 30.3 (21.3–39.4)
[2 vessels 14.5 (10.5–18.7) 6.3 (-2.1–14.6) 12.1 (5.7–18.6)
Culprit vessel 0.212
LAD culprit 48.6 (42.8–54.4) 46.9 (29.6–64.2) 44.4 (34.7–54.2)
Circumflex artery culprit 21.3 (16.5–25.9) 28.1 (12.5–43.7) 17.2 (9.7–24.6)
RCA culprit 19.7 (15.2–24.4) 18.8 (5.2–32.3) 27.3 (18.5–36.0)
Graft culprit 3.1 (1.1–5.1) 3.1 (-2.9–9.2) 8.1 (2.7–13.4)
Left main culprit 7.3 (4.3–10.3) 3.1 (-2.9–9.2) 3.0 (-0.3–6.4)
Restenosis 18.1 (13.6–22.5) 12.5 (1.0–24.0) 20.2 (12.3–28.1) 0.202
De novo lesions 79.5 (74.9–84.2) 81.3 (67.7–94.8) 72.7 (64.0–81.5)
Undetermined 2.4 (0.7–4.2) 6.3 (-2.1–14.6) 7.1 (2.0–12.1)
Treated vessels (n) 452 45 154 N/A
Complete revascularization 22.6 (17.7–27.4) 40.6 (23.6–57.6) 27.3 (18.5–36.0) 0.069
Vessels treated with: 0.475
BMS 21.9 (17.1–26.6) 12.5 (1.0–24.0) 17.2 (9.7–24.6)
DES 67.0 (61.6–71.4%) 78.1 (63.8–92.4) 67.6 (58.5–76.9)
Balloon 11.1 (7.5–14.7) 9.4 (-0.7–19.5) 15.2 (8.1–22.2)
Both BMS and DES 5.9 (3.2–8.6%) 3.1 (-2.9–9.2) 5.1 (0.7–9.4) 0.788
Post-procedural TIMI flow N/A
III 96.9 (94.9–98.9) 96.9 (90.8–102.9) 100 (100.0–100.0)
II 0.7 (-0.3–1.7) 0 0
I 0 0 0
0 2.4 (0.7–4.2) 3.1 (-2.9–9.2) 0
PCI failure 3.1 (1.1–5.1) 3.1 (-2.9–9.2) 0 0.205
Values reported are percentages and 95% confidence intervals when not otherwise specified
N/A not applicable, TIMI Thrombolysis in myocardial infarction, LAD left anterior descending, RCA right coronary artery, BMS bare metal stent,
DES drug eluting stent
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at 30 days [18]. The different end-points considered in our
study (mortality and ischemic events at long term follow-
up) may explain, at least in part, these different results.
The supposed advantages of very early angiography and
intervention are (1) a faster identification of the culprit
lesion that allows a rapid resolution of ischemia with
revascularization [19, 20]; (2) for patients suitable for PCI,
an early intervention may be less frequently associated
with a more organized intracoronary thrombus, that results
in a higher incidence of distal microembolization [8] or
coronary dissection.
On the other hand, the supposed advantages of angi-
ography deferred more than 24 h from hospital admission
are (1) a better assessment of patients’ general clinical
status and comorbidities; (2) a more appropriate pre-
interventional medical management able to reduce the
thrombotic burden, distal microembolization, and renal
complications.
Table 4 Angiographic and procedural characteristics in relation to delay of angiography
\24 h (n = 130; 31.5%) 24–48 h (n = 56; 13.6%) [48 h (n = 227; 54.9%) P value
Coronary artery disease 0.476
One vessel 27.7 (20.0–35.4) 23.2 (12.2–34.3) 19.4 (14.2–24.5)
Two vessels 27.7 (20.0–35.4) 25.0 (13.7–36.3) 30.8 (24.8–36.8)
Three vessels 38.5 (30.1–46.8) 42.9 (29.9–55.8) 38.8 (32.4–45.1)
Left main 6.1 (2.0–10.3) 8.9 (1.5–16.4) 11.0 (6.9–15.1)
Pre-procedural TIMI flow 0.460
III 1.5 (-0.6–3.7) 1.8 (-1.7–5.3) 1.8 (0.1–3.5)
II 34.6 (26.4–42.8) 32.2 (19.9–44.4) 40.1 (33.7–46.5)
I 58.5 (50.0–66.9) 58.9 (46.0–71.8) 48.0 (41.5–54.5)
0 5.4 (1.5–9.3) 7.1 (0.4–13.9) 10.1 (6.2–14.1)
Coronary angioplasty 0.252
1 vessel 66.9 (58.8–75.0) 57.1 (44.2–70.1) 56.8 (50.4–63.3)
2 vessels 24.6 (17.2–32.0) 26.8 (15.2–38.4) 27.3 (21.5–33.1)
[2 vessels 8.5 (3.7–13.2) 16.1 (6.5–25.7) 15.9 (11.1–20.6)
Culprit vessel 0.070
LAD culprit 49.2 (40.6–57.8) 48.3 (35.1–61.3) 46.3 (39.8–52.7)
Circumflex artery culprit 23.9 (16.5–31.2) 26.8 (15.2–38.4) 15.0 (10.3–19.6)
RCA culprit 20.0 (13.1–26.9) 10.7 (2.6–18.8) 27.3 (21.5–33.1)
Graft culprit 2.3 (-0.3–4.9) 7.1 (0.4–13.9) 4.8 (2.1–7.6)
Left main culprit 4.6 (1.0–8.2) 7.1 (0.4–13.9) 6.6 (3.4–9.8)
Restenosis 13.8 (7.9–19.8) 16.1 (6.5–25.7) 21.6 (16.2–26.9) 0.007
De novo lesions 83.1 (76.6–89.5) 73.2 (61.6–84.8) 76.7 (71.1–82.2)
Undetermined 2.4 (1.5–9.3) 6.3 (-1.3–8.4) 7.1 (0.8–5.3)
Treated vessels (n) 184 92 368 N/A
Complete revascularization 33.1 (25.0–41.2) 25.0 (13.7–36.3) 21.1 (15.8–26.5) 0.045
Vessels treated with: 0.152
BMS 15.4 (9.2–21.6) 12.5 (3.8–21.2) 15.0 (10.3–19.6)
DES 78.4 (71.4–85.5) 76.8 (65.7–87.8) 70.0 (64.1–76.0)
Balloon 6.2 (54.8–71.4) 10.7 (2.6–18.8) 15.0 (10.3–19.6)
Both BMS and DES 5.4 (1.5–9.3) 10.7 (2.6–18.8) 4.4 (1.7–7.1) 0.182
Post-procedural TIMI flow N/A
III 98.5 (96.3–100.6) 94.6 (88.7–100.5) 98.2 (96.5–99.9)
II 0 0 0.9 (-0.3–2.1)
I 0 0 0
0 1.5 (-0.6–3.7) 5.4 (-0.5–11.3) 0.9 (-0.3–2.1)
PCI failure 1.5 (-0.6–3.7) 5.4 (-0.5–11.3) 1.8 (0.1–3.5) 0.213
Values reported are percentages and 95% confidence intervals when not otherwise specified
N/A not applicable, TIMI Thrombolysis in myocardial infarction, LAD left anterior descending, RCA right coronary artery, BMS bare metal stent,
DES drug eluting stent
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Our analysis of ACS patients treated with an early
invasive strategy confirms that the relationship between
TnI levels and outcome is maintained even in patients
undergoing early revascularization [1, 21–27], in agree-
ment with FRISC II and GUSTO IV trials [3, 28]. How-
ever, in our population, TnI levels were not independently
associated with mortality and cardiac ischemic events at
long-term follow-up.
Our data confirm also the negative influence on ACS
patients’ outcome of high serum creatinine [29–32], glu-
cose levels [33–36] and low hemoglobin concentration at
admission [37–39], suggesting that an accurate assessment
of comorbidities is very important for ACS patients’ care,
especially when an early invasive strategy is preferred.
The results of our study suggest that complete revas-
cularization is beneficial on long-term outcome, which is at
variance with previous reports [40, 41].
Moreover, in our study, a higher TIMI risk score and a
longer hospital stay are associated with a worse outcome. A
longer hospitalization is generally due to patients’ comor-
bidities or post-procedural complications, and can be
considered an indirect index of clinical complexity.
Our study has some limitations. First, it is an observa-
tional, single-center real-world study, and, although it
faithfully reflects our daily practice, a larger number of
patients should have been enrolled to detect a significant
difference in mortality and cardiac ischemic events with a
higher statistical power. Second, our patients were not
randomized to two different times of angiography, even
though no significant difference in clinical, biohumoral and
angiographic characteristics were observed in the sub-
groups of patients according to different timing and delays
of angiography.
In conclusion, even though our study shows an adher-
ence of our Institution to an early invasive strategy as
suggested by Guidelines, it does not support the concept
that in ACS patients angiography should be performed as
soon as possible after symptom onset or hospital admis-
sion. In fact, in our study a longer time to angiography does
not produce a higher mortality or an increased incidence of
cardiac ischemic events during follow-up. Instead, an
unfavorable long-term outcome is influenced by the clini-
cal complexity of patients, indirectly expressed by a higher
Fig. 1 Follow-up data of study population. UA unstable angina,
NSTEMI Non-ST-elevation myocardial infarction, CABG coronary
artery bypass graft, PCI percutaneous coronary intervention
Fig. 2 Kaplan–Meier survival curves in relation to timing and delay of angiography ([ vs. \24 h)
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TIMI risk score, a longer hospital stay, high serum creat-
inine concentrations, low hemoglobin levels, left ventric-
ular dysfunction, diabetes mellitus, or a positive history for
a previous PCI.
Conflict of interest None.
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